Filippo Fraggetta
Overview
Explore the profile of Filippo Fraggetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
1111
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Eloy C, Bychkov A, Fraggetta F, Temprana-Salvador J, Pantanowitz L, Vielh P
Cytopathology
. 2024 May;
35(4):442-443.
PMID: 38736173
No abstract available.
12.
Pepe P, Pepe L, Pennisi M, Fraggetta F
In Vivo
. 2024 Apr;
38(3):1300-1305.
PMID: 38688647
Background/aim: To evaluate the long-term oncological outcomes in men with intermediate risk prostate cancer (PCa) enrolled in active surveillance (AS). Patients And Methods: From April 2015 to December 2022, 30...
13.
Malapelle U, Passiglia F, Pepe F, Pisapia P, Reale M, Cortinovis D, et al.
Lung Cancer
. 2024 Apr;
191:107787.
PMID: 38593479
Aims: To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for the clinical stratification...
14.
Pepe P, Pepe L, Curduman M, Pennisi M, Fraggetta F
Arch Ital Urol Androl
. 2024 Feb;
96(1):12132.
PMID: 38363231
Introduction: To evaluate the accuracy of PSMA PET/CT in the diagnosis and clinical staging of prostatic ductal adenocarcinoma (DAC). Materials And Methods: Two Caucasian men 58 and 62 years old...
15.
Pepe P, Fandella A, Barbera M, Martino P, Merolla F, Caputo A, et al.
Pathologica
. 2024 Feb;
116(1):1-12.
PMID: 38349336
Multiparametric magnetic resonance imaging (mpMRI) has improved systematic prostate biopsy procedures in the diagnosis of clinically significant prostate cancer (csPCa) by reducing the number of unnecessary biopsies; numerous level one...
16.
Caputo A, Angeloni M, Merolla F, Vatrano S, Ferrazzi F, Fraggetta F
J Clin Pathol
. 2024 Jan;
77(6):426-429.
PMID: 38267209
In the fully digital Caltagirone pathology laboratory, a reverse shift from a digital to a manual workflow occurred due to a server outage in September 2023. Here, insights gained from...
17.
Malapelle U, Donne A, Pagni F, Fraggetta F, Guerini Rocco E, Pasello G, et al.
Crit Rev Oncol Hematol
. 2023 Dec;
193:104217.
PMID: 38040072
Molecular biomarker testing is increasingly becoming standard of care for advanced non-small cell lung cancer (NSCLC). Tissue and liquid biopsy-based next-generation sequencing (NGS) is now highly recommended and has become...
18.
Menotti L, Silvello G, Atzori M, Boytcheva S, Ciompi F, Di Nunzio G, et al.
J Pathol Inform
. 2023 Sep;
14:100332.
PMID: 37705689
Material And Methods: This paper presents the ExaMode ontology, modeling the histopathology process by considering 3 key cancer diseases (colon, cervical, and lung tumors) and celiac disease. The ExaMode ontology...
19.
Cazzaniga G, Bolognesi M, Stefania M, Mascadri F, Eccher A, Alberici F, et al.
Lab Invest
. 2023 Aug;
103(11):100243.
PMID: 37634845
Renal amyloidosis is a rare condition caused by the progressive accumulation of misfolded proteins within glomeruli, vessels, and interstitium, causing functional decline and requiring prompt treatment due to its significant...
20.
Caputo A, Macri L, Gibilisco F, Vatrano S, Taranto C, Occhipinti E, et al.
J Am Soc Cytopathol
. 2023 Jul;
12(5):378-385.
PMID: 37482510
Introduction: Cervical cancer is the fourth most common cancer in women, and its prevention is based on vaccination and screening. Screening consists of molecular human papillomavirus (HPV) testing and cytologic...